Emerging Molecular Blood Banking and NAT Screening Technologies and Strategic Profiles of Leading Suppliers

November 2021 | | ID: 2133138044BEN
Venture Planning Group

Abstracts

This report provides assessments of such technologies as molecular diagnostics, monoclonal and polyclonal antibodies, immunoassays, microtitration plates, IT, lasers, synthetic red cell substitutes, genetically engineered blood components, blood preservation, autologous blood transfusion/freezing and their potential applications for blood banking.

The report also presents strategic assessments of current and emerging suppliers of blood banking products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Contents

CURRENT AND EMERGING TECHNOLOGIES

MOLECULAR DIAGNOSTICS

a. Overview
b. NAT

MONOCLONAL AND POLYCLONAL ANTIBODIES

IMMUNOASSAYS

a. Technological Principle
b. Chemiluminescence
c. Enzyme Immunoassays (EIA)
  Overview
  ELISA
  EMIT
  Electrochemical
d. Radioimmunoassays (RIA)
e. Immunoprecipitation
f. Affinity Chromatography

MICROTITRATION PLATES

IT and Automation
Lasers
Robotics
Synthetic Red Cell Substitutes

GENETICALLY ENGINEERED BLOOD COMPONENTS

a. Albumin
b. Factor VIII
c. Alpha-2 Antiplasmin
d. Antithrombin III
e. Factor IX
f. Von Willebrand's Factor
g. Fibrinogen
h. t-PA

BLOOD PRESERVATION

AUTOLOGOUS BLOOD TRANSFUSION/FREEZING

COMPETITIVE PROFILES

Abbott
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Diagast
DiaSorin
Fujirebio
Grifols
Hologic
Immucor
LabCorp
Ortho-Clinical Diagnostics
Proteome Sciences
Quest Diagnostics
Quidel
Roche
Siemens Healthineers
Tecan
Thermo Fisher